Oxford/AZ Vaccine Hits 70% Efficacy In Phase III Trials
90% Response Seen In Half Dose Trial
Topline results have produced a lower efficacy rate than seen in the Pfizer and Moderna trials, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
You may also be interested in...
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
Russia is promising the best of both worlds – a low price with a near-perfect efficacy. While the basic science is plausible, its best-in-class claims are bound to generate skepticism.